Welcome to our dedicated page for Cibus SEC filings (Ticker: CBUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cibus, Inc.'s SEC filings document an agricultural biotechnology company that uses proprietary gene-editing technologies to develop plant traits for licensing to seed companies. The filings describe its royalty-oriented model, productivity traits for major agricultural food crops, and trait categories tied to weeds, pests, diseases, sustainability and yield challenges.
The company's regulatory record includes 8-K material-event reports, financial-results exhibits, proxy materials, governance disclosures and capital-structure information for its Class A common stock. These filings also cover board appointments, compensatory arrangements, shareholder voting matters, material agreements, registered securities and business disclosures related to the development and commercialization of gene-edited crop traits.
Cibus, Inc. reported that Sr VP, Research Noel Sauer received an equity compensation grant. Sauer acquired 38,000 shares of Class A Common Stock at $0.00 per share as an award, bringing direct holdings to 139,879 shares.
Sauer was also granted a stock option for 76,000 shares of Class A Common Stock at an exercise price of $1.50 per share, expiring on April 24, 2036. According to the footnote, 1/48th of the total options vest monthly on the 24th of each month until the fourth anniversary of the grant date.
Cibus, Inc. granted Chief Administrative Officer, General Counsel and Corporate Secretary Jason Stokes 57,000 shares of Class A Common Stock as an equity award. He now directly holds 167,865 shares after this grant.
The company also awarded him a stock option for 114,000 shares of Class A Common Stock at an exercise price of $1.50 per share. According to the vesting terms, 1/48 of the options vest monthly on the 24th until the fourth anniversary of the grant date, and the options expire on April 24, 2036. These are compensation-related awards, not open-market purchases or sales.
Cibus, Inc. reported that its CFO, Carlo Broos, received equity-based compensation. He was granted 57,000 shares of Class A Common Stock at no cost, bringing his direct holdings to 154,275 shares.
He was also granted 114,000 stock options to buy Class A Common Stock at an exercise price of $1.50 per share, exercisable starting on April 24, 2027 and expiring on April 24, 2036.
Gocal Gregory Francis William reported acquisition or exercise transactions in this Form 4 filing.
Cibus, Inc. reported that Chief Scientific Officer & EVP Gregory Francis William Gocal received equity awards on April 24, 2026. He was granted 57,000 shares of Class A common stock and 114,000 stock options to buy Class A common at $1.50 per share.
Following the grant, he directly holds 422,890 common shares and 114,000 options. According to the vesting terms, 1/48th of the options vest monthly on the 24th of each month until the fourth anniversary of the grant date.
Cibus, Inc. reported that Interim CEO, President and COO Peter Beetham received an equity compensation grant. He was awarded 195,000 shares of Class A common stock on April 24, 2026 at a price of $0.00 per share, bringing his direct holdings to 686,825 shares.
He also received a stock option for 390,000 shares of Class A common stock with an exercise price of $1.50 per share, exercisable until April 24, 2036. According to the vesting terms, 1/48th of the options vest monthly on the 24th of each month over four years from the grant date.
Cibus, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 2, 2026 at 10:00 a.m. Pacific Time. The agenda includes electing nine directors for one-year terms, approving on an advisory basis the compensation of named executive officers, and ratifying BDO USA, P.C. as independent auditor for the year ending December 31, 2026.
Holders of Class A Common Stock as of April 6, 2026, when 76,345,736 shares were outstanding, are entitled to one vote per share. The board is currently ten members but expects to reduce to nine after director Keith Walker steps down. Seven of nine post‑meeting directors are expected to be independent under Nasdaq rules, and the roles of Chairman and Interim Chief Executive Officer are separated.
The proxy describes detailed voting procedures for stockholders of record and beneficial owners, quorum requirements, the treatment of abstentions and broker non‑votes, and deadlines for submitting stockholder proposals or director nominations for the 2027 annual meeting. It also outlines the board’s committee structure, governance policies, insider trading and hedging restrictions, and a clawback policy for incentive-based compensation.
Cibus, Inc. director Urban Thomas filed an initial Form 3 reporting his beneficial ownership in the company. The filing shows he held 0 shares of Class A Common Stock directly at the time of the report and does not list any recent purchases, sales, or option exercises.
Cibus, Inc. reported that its Board of Directors appointed Thomas Urban as a director, effective April 7, 2026. Urban is the founder of Agribusiness Advisors and has held leadership roles at CellFor, ArborGen, and Pioneer Hi-Bred International, and began his career at Goldman Sachs.
He will enter into the company’s standard indemnification agreement for directors and, under the Non-Employee Director Compensation Policy, will receive a $60,000 annual cash retainer and equity awards with a grant date value of $90,000, both prorated through the next annual shareholder meeting.
Cibus, Inc. senior vice president of research Noel Sauer reported a routine tax-withholding disposition of 1,763 shares of Class A Common Stock on March 30, 2026. The shares were valued at a weighted average price of $1.84 per share. After this transaction, Sauer directly owns 101,879 shares of Cibus stock.